Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease.

NCT06637631 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06637631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06637631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease.
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
December 10, 2024
Completion date
October 2, 2026
Enrollment
105 (actual)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease